This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of dicloxacillin: A Synthesis of Findings from 24 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of dicloxacillin: A Synthesis of Findings from 24 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Dicloxacillin has been shown to be effective against various strains of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). 24 . Dicloxacillin inhibits the first step in wall teichoic acid biosynthesis (TarO), which weakens the cell wall of MRSA and makes it more susceptible to β-lactam antibiotics. 24 .

In a mouse peritonitis model, dicloxacillin demonstrated intracellular activity against Staphylococcus aureus. 14 . Dicloxacillin was found to accumulate inside cells more effectively than other antibiotics and significantly reduced the number of intracellular bacteria. 14 .

Dicloxacillin exhibited similar bactericidal activity compared to vancomycin against oxacillin-susceptible mecA-positive Staphylococcus aureus (OS-MRSA) clinical isolates, as evaluated by population analyses, time-kill assays, and a murine thigh infection model. 2 . These findings suggest that antistaphylococcal penicillins, like dicloxacillin, may be effective against OS-MRSA infections. 2 .

Dicloxacillin demonstrated synergistic effects with the phenothiazine drug thioridazine against MRSA, vancomycin intermediate-susceptible S. aureus (VISA), and methicillin-resistant Staphylococcus epidermidis (MRSE). 20 . This synergy suggests that cell wall thickening does not interfere with the effects of thioridazine. 20 .

Benefits and risks

Benefit Summary

Dicloxacillin could be a viable treatment option for various Staphylococcus aureus infections, including MRSA. 24 , 2 . Dicloxacillin accumulates efficiently within cells and can effectively reduce the number of intracellular bacteria. 14 . Synergistic effects have been observed when combining dicloxacillin with thioridazine against MRSA, VISA, and MRSE, suggesting potential for enhanced treatment approaches. 20 .

Risk Summary

Similar to other antibiotics, dicloxacillin poses potential side effects. 13 . Common side effects include gastrointestinal disturbances (diarrhea, nausea, vomiting), rash, and liver dysfunction. 13 . Dicloxacillin may interact with anticoagulants like warfarin. .

Comparison of studies

Commonalities in studies

Numerous studies have highlighted the effectiveness of dicloxacillin as a treatment option for Staphylococcus aureus infections. 24 , 14 , 2 , 20 . A common theme is the potential for enhanced efficacy when dicloxacillin is combined with other antibiotics. 24 , 20 .

Differences in studies

The effectiveness of dicloxacillin can vary depending on the specific strain of Staphylococcus aureus and the combination of drugs used. 24 , 2 , 20 . Individual patient factors, such as age, gender, and kidney function, can also influence the effectiveness of dicloxacillin. 18 , 4 .

Consistency and contradictions in the results

While various studies consistently demonstrate the effectiveness of dicloxacillin against Staphylococcus aureus infections, 24 , 14 , 2 , 20 , there is a suggestion of variability in its effectiveness based on the specific strain of Staphylococcus aureus and the combination of drugs used. 24 , 2 , 20 . Tailoring treatment strategies to individual patients is crucial to maximize the therapeutic benefits of dicloxacillin. 18 , 4 .

Considerations for applying the results to real life

It is crucial to take dicloxacillin as prescribed by a healthcare professional. 13 . Self-adjusting dosages or discontinuing the medication without medical advice may worsen infections. 13 . Dicloxacillin can interact with other medications like anticoagulants (warfarin), so it is essential to inform your doctor about any other drugs you are taking. .

Limitations of current research

Current research on the effects of dicloxacillin is still limited. 24 , 14 , 2 , 20 . Further investigation is required to fully understand the impact of dicloxacillin across various Staphylococcus aureus strains, its interactions with other medications, and its long-term effects and safety. 24 , 2 , 20 , 18 , 4 .

Future research directions

To gain a more comprehensive understanding of dicloxacillin's effects, further research is needed to explore its efficacy across a wider range of Staphylococcus aureus strains, its interactions with other medications, and its long-term effects and safety. 24 , 2 , 20 , 18 , 4 .

Conclusion

Dicloxacillin shows potential as an effective treatment for Staphylococcus aureus infections. 24 , 14 , 2 , 20 . However, it is crucial to acknowledge the potential for variability in its effectiveness based on the specific strain of Staphylococcus aureus and the combination of drugs used. 24 , 2 , 20 . To maximize therapeutic benefits, personalized treatment approaches tailored to individual patients are essential. 18 , 4 .


Literature analysis of 24 papers
Positive Content
19
Neutral Content
1
Negative Content
4
Article Type
2
0
0
0
24

Language : English


Language : English


Language : English


Language : Icelandic


Language : English


Language : English


Language : English


Language : English


Language : German


Language : English


Author: SandbergAnne, HesslerJonas H R, SkovRobert L, BlomJens, Frimodt-MøllerNiels


Antibiotic treatment of Staphylococcus aureus infections is often challenging due to slow responses and high recurrence rates. Intracellular persistence of staphylococci has been recognized as a contributing factor. This study used a mouse peritonitis/sepsis model to explore the interplay between intracellular antibiotic activity and the overall outcome of infection. The study used a quantitative ex vivo extra- and intracellular differentiation assay to assess the intracellular presence of S. aureus, which was also confirmed by electron microscopy. Five antibiotics, dicloxacillin, cefuroxime, gentamicin, azithromycin, and rifampin (rifampicin), were tested in the new in vivo model. The intracellular effects of these antibiotics were ranked as follows, based on the mean change in the log(10) number of CFU/ml (Delta log(10) CFU/ml) between treated and untreated mice after 4 hours of treatment: dicloxacillin (3.70 Delta log(10) CFU/ml) > cefuroxime (3.56 Delta log(10) CFU/ml) > rifampin (1.86 Delta log(10) CFU/ml) > gentamicin (0.61 Delta log(10) CFU/ml) > azithromycin (0.21 Delta log(10) CFU/ml). The study also highlighted the importance of dose size, number, and frequency, time of exposure, and the timing between infection onset and treatment in testing intracellular activity in vivo. A poor correlation was found between intracellular antibiotic accumulation and the actual intracellular effect, emphasizing the need for experimental studies like those described here to measure actual intracellular activity instead of relying solely on cellular pharmacokinetic and MICs.

Language : English


Language : English


Language : English


Language : English


Language : English


Author: LeeSang Ho, WangHao, LabroliMarc, KoseogluSandra, ZuckPaul, MayhoodTodd, GillCharles, MannPaul, SherXinwei, HaSookhee, YangShu-Wei, MandalMihir, YangChristine, LiangLianzhu, TanZheng, TawaPaul, HouYan, KuvelkarReshma, DeVitoKristine, WenXiujuan, XiaoJing, BatchlettMichelle, BalibarCarl J, LiuJenny, XiaoJianying, MurgoloNicholas, GarlisiCharles G, ShethPayal R, FlatteryAmy, SuJing, TanChristopher, RoemerTerry


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.